Ignite Creation Date:
2024-05-06 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05292131
Status:
COMPLETED
Last Update Posted:
2023-12-22
First Post:
2022-03-14
Brief Title:
A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-17
Start Date Type:
ACTUAL
Primary Completion Date:
2023-01-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-01-09
Completion Date Type:
ACTUAL
First Submit Date:
2022-03-14
First Submit QC Date:
March 14 2022
Study First Post Date:
2022-03-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-18
Last Update Post Date:
2023-12-22
Last Update Post Date Type:
ACTUAL